Vivimed Labs Ltd

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 May 2026, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 12 August 2026, providing investors with the latest data to understand the rationale behind this rating.

At Rs 5.12, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 4.92% on 11 Aug 2026, with buyers queuing and no sellers willing to part with shares.

For the second consecutive session, Vivimed Labs Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 4.76 on 11 Aug 2026. This decline comes despite a relatively stable broader market, underscoring stock-specific headwinds that continue to weigh on investor sentiment.

For the second consecutive session, Vivimed Labs Ltd closed at a fresh all-time low of Rs.4.76 on 11 Aug 2026, extending a steep decline that has seen the stock lose over 72% year-to-date, far underperforming the broader market.

For the fifth consecutive session, Vivimed Labs Ltd closed lower, hitting a fresh 52-week low of Rs 4.83 on 10 Aug 2026, marking a significant decline from its 52-week high of Rs 27.99. This persistent downtrend comes despite a broadly positive market backdrop, underscoring stock-specific pressures weighing on the micro-cap.

Vivimed Labs Ltd’s stock price has declined to an all-time low of ₹4.83 on 10 August 2026, marking a significant milestone in the company’s extended period of underperformance. This latest drop reflects a continuation of the stock’s bearish trajectory, with the share price now hovering just 2.58% above its 52-week low of ₹4.91.

Vivimed Labs Ltd’s share price declined to a fresh 52-week low of Rs.4.91 on 7 August 2026, marking a significant drop from its 52-week high of Rs.27.99. The stock’s performance reflects ongoing financial pressures and market sentiment, with the company’s Mojo Grade recently downgraded to Strong Sell by MarketsMOJO.

At Rs 5.33, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 5% on 3 Aug 2026, with buyers queuing and no sellers willing to part with shares.

For the second consecutive session, Vivimed Labs Ltd has slipped further, hitting a fresh 52-week low of Rs 4.95 on 3 Aug 2026, despite broader market gains. This decline extends the stock’s downward momentum, contrasting sharply with the rally in major indices.

At Rs 4.94, sellers were still queuing — but there were no buyers willing to take the other side. Vivimed Labs Ltd locked at its lower circuit of 5% on 29 Jul 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock with limited liquidity.

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 May 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 29 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

A sustained decline has pushed Vivimed Labs Ltd to its lowest price in 52 weeks, reflecting ongoing concerns over its financial health and market positioning despite recent minor gains.

At Rs 5.33, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 2.76% on 17 Jul 2026, with buyers queuing and no sellers willing to part with shares.

For the fifth consecutive session, Vivimed Labs Ltd closed lower, slipping to a fresh 52-week low of Rs 5 on 17 Jul 2026, marking a 9.26% decline over this losing streak despite a broadly positive market backdrop.

A sustained decline over four consecutive sessions has dragged Vivimed Labs Ltd to a fresh 52-week low of Rs 5.04 on 16 Jul 2026, marking a significant drop from its peak of Rs 23.94 in the past year.

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 May 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 16 July 2026, providing investors with the latest perspective on the company’s position.